WO1992011859A1 - Peptide-mediated hyposensitization of the human t cell response to dermatophagoides spp. (house dust mite) - Google Patents
Peptide-mediated hyposensitization of the human t cell response to dermatophagoides spp. (house dust mite) Download PDFInfo
- Publication number
- WO1992011859A1 WO1992011859A1 PCT/US1992/000205 US9200205W WO9211859A1 WO 1992011859 A1 WO1992011859 A1 WO 1992011859A1 US 9200205 W US9200205 W US 9200205W WO 9211859 A1 WO9211859 A1 WO 9211859A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- allergen
- peptide
- molecules
- derived
- cell
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 95
- 230000005867 T cell response Effects 0.000 title claims description 23
- 239000000428 dust Substances 0.000 title claims description 13
- 241000238710 Dermatophagoides Species 0.000 title description 8
- 230000001404 mediated effect Effects 0.000 title description 3
- 239000013566 allergen Substances 0.000 claims abstract description 89
- 230000004936 stimulating effect Effects 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 36
- 108091054438 MHC class II family Proteins 0.000 claims abstract description 27
- 102000043131 MHC class II family Human genes 0.000 claims abstract description 16
- 230000028993 immune response Effects 0.000 claims abstract description 15
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 36
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims description 16
- 150000001413 amino acids Chemical group 0.000 claims description 15
- 230000004044 response Effects 0.000 claims description 15
- 230000027455 binding Effects 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 241000712461 unidentified influenza virus Species 0.000 claims description 9
- 230000000638 stimulation Effects 0.000 claims description 6
- 230000005859 cell recognition Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 241000238711 Pyroglyphidae Species 0.000 claims 2
- 229940046533 house dust mites Drugs 0.000 claims 2
- 108700005092 MHC Class II Genes Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 19
- 210000004027 cell Anatomy 0.000 description 18
- 239000000427 antigen Substances 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 13
- 101710154606 Hemagglutinin Proteins 0.000 description 11
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 11
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 11
- 101710176177 Protein A56 Proteins 0.000 description 11
- 208000026935 allergic disease Diseases 0.000 description 11
- 239000000185 hemagglutinin Substances 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 10
- 241000238713 Dermatophagoides farinae Species 0.000 description 8
- 238000007792 addition Methods 0.000 description 7
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000000586 desensitisation Methods 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102100029829 28S ribosomal protein S29, mitochondrial Human genes 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 101000727490 Homo sapiens 28S ribosomal protein S29, mitochondrial Proteins 0.000 description 2
- 101000844774 Homo sapiens Disks large-associated protein 3 Proteins 0.000 description 2
- 101001081189 Homo sapiens Rho GTPase-activating protein 45 Proteins 0.000 description 2
- 206010039094 Rhinitis perennial Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 108010011505 fluorescein-avidin Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 101710186708 Agglutinin Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- -1 DRw52b Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 102000009485 HLA-D Antigens Human genes 0.000 description 1
- 108010048896 HLA-D Antigens Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- IQFYYKKMVGJFEH-ZEIUMXODSA-N alpha-tritiated thymidine Chemical compound O=C1NC(=O)C(C[3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-ZEIUMXODSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- DASQOOZCTWOQPA-GXKRWWSZSA-L methotrexate disodium Chemical compound [Na+].[Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 DASQOOZCTWOQPA-GXKRWWSZSA-L 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108010086652 phytohemagglutinin-P Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- atopic allergy is applied to a group of allergies, including asthma, hay fever, allergic rhinitis, urticaria (hives), eczema, conjunctivitis and food allergies, all of which are induced by environmental antigens.
- the mechanisms include the synthesis of specific immunoglobulin E (IgE) with the differentiation and growth of effector cells such as mast cells and eosiniphils. The activity of these effector cells is dependent upon T-helper (CD4+) cells and their products.
- IgE immunoglobulin E
- CD4+ T-cells are dependent upon antigen receptors on T-cells recognizing peptide fragments of foreign proteins (allergens) in association with self gene products of the major histocompatibility complex (MHC) expressed on the surface of antigen presenting cells.
- allergens peptide fragments of foreign proteins
- MHC major histocompatibility complex
- Allergic IgE-mediated diseases are currently treated by desensitization procedures that involve the periodic injection of allergen components or extracts. Desensitization treatments may induce an IgG response that competes with IgE for allergen, or they may induce specific suppressor T-cells that block the synthesis of IgE directed against allergen. These procedures are not always effective and pose the risk of provoking an allergic response.
- a therapeutic treatment that would decrease or eliminate the allergic-immune response to a particular allergen, without altering the immune reactivity to other foreign antigens or triggering an allergic response itself would be of great benefit to allergic individuals.
- the present invention is a method of reducing T cell response to a selected allergen, in which a non-allergen derived, non-stimulatory peptide is used and interferes with T cell recognition of the aller ⁇ gen, resulting in a decreased T cell response.
- the present invention is useful in reducing (decreasing or eliminating) hypersensitivity of an individual to an allergen.
- a non-allergen derived, non-stimulatory peptide is administered to the individual to modulate T cell recognition of the allergen and, as a result, to reduce the individual's immune response to the allergen.
- the non-allergen derived, non-stimulatory peptide admin- istered is one which binds to selected MHC class II molecules of antigen presenting cells and, as a result, inhibits the specific T-helper cell response.
- the present invention further relates to peptides and compositions useful in the method of reducing hyper- sensitivity.
- the present invention relates to a method of reducing hypersensitivity of an individual to Dermatophagoides spp. (house dust mite or HDM) . It also relates to non-HDM derived non-stimulatory peptides, such as non-stimulating peptide analogs of influenza haemagglutinin which bind to DRw52b class II molecules, useful in the present method.
- non-HDM derived non-stimulatory peptides such as non-stimulating peptide analogs of influenza haemagglutinin which bind to DRw52b class II molecules, useful in the present method.
- the invention in another embodiment, relates to an in vitro method of determining the capability of a non-allergen derived, non-stimulatory peptide to reduce the immune response to an allergen. This is achieved by determining whether the peptide binds to specific MHC class II molecules of antigen presenting cells and whether binding of the peptide to specific MHC class II molecules modulates the T-cell MHC-restricted recognition of the allergen, thereby reducing the immune response to the allergen.
- Currently used methods of achieving hyposensi- tization to allergens, including Dermatophagoides spp. depend upon the administration of the components or extracts of allergens. However, these components or extracts are not always successful and can themselves provoke allergic responses.
- the present invention provides an alternative approach to such therapy and is particularly advantageous because desensitization can be achieved while the risk of triggering an allergic response is reduced.
- Figure 1 is a graphic representation of HA S-309 induced inhibition of the polyclonal T-cell response of dust mite allergic individuals to specific allergen.
- Figure 2 is a graphic representation of HA S-309 modulation of polyclonal T-cell responses to Dermatophagoides spp., M. tuberculosis and PHA.
- Figure 3 is a graphic representation of HA S-309 modulation of monoclonal T-cell responses to insolu- bilized anti-CD3 antibody and Dermatophagoides spp.
- Figure 4 is a graphic representation of the binding of HA S-309 to DRw52b HLA class II molecules expressed on the surface of murine fibroblasts.
- the present invention is based on the discovery that a non-allergen derived, non-stimulatory peptide is able to bind to selected MHC class II molecules and inhibit both polyclonal and monoclonal T cell response to an allergen (referred to as an allergen of interest) which causes a T cell response in allergic individuals.
- an allergen of interest referred to as an allergen of interest
- a non-stimulatory peptide analogue derived from influenza virus hemagglutinin (HA) binds selected MHC class II molecules and inhibits the reponse of mite- specific CD4+ T cells restricted by the MHC class II molecules.
- T-cell MHC- restricted recognition is defined as a response of a T-cell resulting from an interaction with a MHC class II molecule of an antigen presenting cell and an allergen derived peptide.
- the present invention relates to a method of reducing (decreasing or eliminating) a specific allergic response by an individual to an allergen by administering to the individual a peptide which is not derived from the allergen to which the response occurs, is itself non-stimulatory, and binds to MHC class II molecules which also bind the allergen.
- the invention relates to a method of reducing T cell recognition of HDM through the use of a peptide analogue derived from influenza virus HA.
- an individual's sensitivity to an allergen such as HDM can be reduced by administering to the individual a therapeutically effective dose of a non-allergen derived, non-stimulatory peptide, which binds to specific MHC class II molecules of antigen- presenting cells. This binding inhibits the T-cell response to the allergen and thereby, decreases or eliminates the allergic response.
- the non-allergen derived, non-stimulatory peptide used in the present method is one derived from or having essentially the same sequence as a peptide from a source other than the allergen of interest. It can have the same (unmodified) amino acid sequence as occurs in the peptide from which it is derived or can have an altered amino acid sequence (i.e., is a peptide "analogue" which differs from the amino acid sequence as it occurs naturally by deletion, addition or substitution of at least one amino acid) .
- the term "derived from” includes both amino acid sequences (peptides) physically obtained from an existing sequence (e.g., by cutting or cleaving using chemical or enzymatic processes) and amino acid sequences which are produced, using known methods such as genetic engineering techniques or synthetic chem ⁇ istry to have substantially the same sequence as that of an existing sequence.
- the term peptide is intended to include both unmodified and modified amino acid sequences.
- the non-allergen derived, non-stimulatory peptide can be any peptide that does not provoke a response to the allergen to which desensitization is desired, binds a site on a MHC class II surface molecule of an antigen-presenting cell to which the allergen can also bind, and inhibits the T-cell response to the aller ⁇ gen.
- a peptide analogue (designated S-309) derived from the natural sequence of the carboxyl terminus of the HA-1 peptide of influenza hae agglutinin (residues 307-319, with the tryosine at position 309 substituted by serine) is used.
- S-309 binding is restricted to a particular MHC class II molecule, whereas the native peptide is non-restricted in the number of MHC class II molecules it has the capabity to bind.
- this peptide analogue has been shown to bind class II molecules which also bind HDM and to inhibit the antigen- dependent re ⁇ sponse of cloned HDM specific T cells with the same restriction specificity.
- the S-309 peptide analogue having the sequence:
- a peptide analogue useful in the present method differs from the normally-occurring peptide by at least one amino acid (e.g., an addition, deletion or substitution) . Alterations in the amino acid sequence can be made to enhance the ability of the peptide analogue to inhibit T cell response to the allergen.
- Peptides and peptide analogues can be prepared by a variety of known methods. For example, they can be prepared using Merrifield's procedure of solid-phase peptide synthesis (Merrifield, R.B., J. Am. Chem. Soc. , 86; 304 (1964), hereby incorporated by refer- ence) .
- the first step in the solid-phase synthesis of amino acid peptide analogues, as well as other pep ⁇ tides, is the formation of a covalent bond between the C-terminal protected amino acid of the chosen peptide sequence and the solid support or resin.
- the peptide chain is then build up residue by residue by repeti ⁇ tive cycles of deprotection, during which the N- ternamal Boc-protecting (N-tect-bitoxycarboxyl) group is removed by trifluoroacetic acid (TFA) . This is followed by neutralization with disopropylethylamine (DEA) of the amino group left as a salt and coupling of the next amino acid in the sequence. The cycle is repeated until the sequence is completed.
- DEA disopropylethylamine
- peptides useful in the present invention can be produced using genetic engineering techniques.
- DNA encoding the desired amino acid sequence can be incorporated into an appropriate expression vector and introduced into a host cell suitable for expression of the encoded product.
- Administration of the non-stimulatory peptide to an individual can be by any route by which a therapeu- tically effective quantity of the peptide can be delivered.
- administration can be via a parenteral route, such as by subcutaneous, intravenous or intramuscular administration, transdermal passage or uptake from the respiratory tract.
- Administration can also be via the gastrointestinal tract, such as by oral or rectal administration.
- the form in which the peptide is administered (e.g., capsule, tablet, solution, emulsion) will depend, at least in part, on the route by which it is administered.
- administration by injection would involve the use of physiologic saline or other physiological compatible carrier.
- a therapeutically effective amount of a non- stimulatory peptide is that amount which will decrease or eliminate the T-helper cell response to a specific allergen.
- the therapeutically effective amount will be determined on an individual basis and will be based, at least in part, on consideration of the individual's size, the severity of symptoms to be treated, the result sought, the particular non- stimulatory peptide used, etc.
- the effective amount can be determined by one of ordinary skill in the art employing such factors and using no more than routine experimentation.
- the non-allergen derived, non-stimulatory peptides used in the method of the present invention bind to ⁇ IHC class II molecules and interfere with the recognition of allergen MHC-molecule complexes by T-helper cells. As a consequence, the T-cell response is inhibited. This inhibition is reflected by a lack of clonal expansion and the secretion of one or more lymphokines which are soluble factors that have multiple effects on B-cells and other T-cells. Lack of or decrease in a T-cell response to an allergen is referred to as a hyposensitization of the T-cells to the allergen.
- non-allergen non-stimulating peptides of influenza haemagglutinin which is used to modulate the immune response to HDM
- Identification of other inhibitors of specific allergens can be achieved by 1) identifying the specificity of the restriction (MHC class II) molecules of importance with the specific allergen; 2) searching the database for peptides known to bind to these molecules; 3) synthesizing and testing the above peptides for their ability to inhibit binding of and/or recognition of the allergen in a competition assay; and 4) modifying peptides to produce peptide analogues with enhanced binding and/or biological activity.
- peptides can be randomly selected and screened for their capacity to bind specific MHC class II molecules and inhibit allergen-dependent T-cell proliferation.
- Lyophilized extracts of Dermatophagoides farinae (D. farinae) and Dermatophagoides pteronyssinun (D. pteronyssinun) were the general gifts of Drs. Lowenstein and Schou (ALK, Horsholm, Denmark) and Bencard (Brentford, Middlesex, U.K.), respectively.
- a soluble extract of Mycobacteriu tuberculosis (MTSE) was generously provided by Dr. A. Rees (M.R.C.
- HA peptide analogue (residues 307-319: serine at 309) and the keratin peptide (residues 1-9) were synthesized using solid phase techniques (Barany, G. and Merrifield, R. , Solid phase peptide synthesis In: Gross, E. Meinhofer, J. (Eds), The Peptides, New York, Academic Press (1979) hereby incorporated by reference) on an Applied Biosystems Peptide Synthesizer with Pam resins, t-Boc protected amino acids, and commercially available reagents (Applied Biosystems, Foster City, CA) . Peptides were kindly provided by J.
- the T cell mitogen phytahaemagglutinin (PHA-P) was purchased from Sigma Chemicals Co. (St. Louis, MO) , and the murine monoclonal anti-CD3 antibody (OKT3) purified from the hybridoma cell line purchased from the ATCC (Rockville, MD) .
- PBMC Peripheral blood mononuclear leucocytes obtained from unmedicated atopic adults with symptomatic HDM allergy (perennial rhinitis) were isolated by centrifugation on a discontinuous gradient of Ficoll-Paque (Pharmacia) . All subjects had positive skin prick tests to Dermaphatogoides spp., and positive HDM radioallergosorbent tests.
- PBMC were resuspended in complete medium, RPMI-1640 supplemented with A+ or AB+ serum, 2mM L-glutamine and 100 IU/ml of penicillin/streptomycin.
- HDM specific T cell clones were isolated as described previously (O'Hehir, R.E., et al. ,
- PBMC 2.5 X 5 10 /ml
- D farinae 7 days in complete medium.
- Lymphoblasts enriched on Ficoll-Paque were maintained as a long term line in the presence of irradiated
- T cell clones Prior to their use in proliferation assays, the T cell clones were rested for 6-8 days after the last addition of filler cells and antigen. A number of T cell clones specific for D. Farinae and others cross-reactive with D. farinae and D. pteronyssiunus were isolated, and the MHC class II restriction specificities of these clones were mapped (O'Hehir, R.E., et al. , Immunology, 64: 627 (1988)).
- PBMC 2.5 X 10 /ml were cultured with soluble antigen in a total volume of 200 ⁇ l of complete medium in 96-well round bottom plates.
- Peptides were added at various concentrations to selected wells at the initiation of cultures. After 6 days, tritiated methyl thymidine (l ⁇ Ci [ H] .
- TdR/well Amersham International, Amersham, U.K.
- Amersham International Amersham, U.K.
- Proliferation as correlated with [ H] -TdR incorporation was measured at day 7 by liquid scintillation spectroscopy. The results are expressed as mean counts per minute (cpm) for triplicate cultures.
- PHA and anti-CD3 induced activation PHA at a concentration of 1 ⁇ g/ml induced marked proliferation in each subject (see Figures 2C i and ii) . No inhibitory effect was observed with the addition of either peptide. Similarly, both peptides failed to inhibit the proliferative response of T cells stimulated directly with immobilized anti-CD3 antibody and IL-2 that mimics the recognition of peptide/MHC class II complexes as illustrated in Figure 3A i.
- Example I Cloned T cells (5 X 10 /ml) were cultured with soluble antigen in the presence of irradiated
- D. pteronyssinus (3 ⁇ g/ml) presented by autologous irradiated PBMC as accessory cells.
- the addition of the HA analogue resulted in marked inhibition of the proliferative response in a dose dependent manner, with 60% inhibition at 100 ⁇ g/ml.
- coculture using the keratin peptide failed to inhibit the HDM induced proliferation as illustrated in Figure
- D. farinae specific T cell clones (DE12 and DE47) restricted by the DRAB3 gene product DRw52b and T cell clone DE9 were stimulated with increasing concentra ⁇ tions of stimulating antigen (D. farinae) in the presence of autologous irradiated PBMC as a source of antigen presenting cells.
- the HA analogue was added at a fixed concentration (100 ⁇ g/ml) and T cell proliferation determined.
- the HA peptide was able to compete with HDM for presentation to the cloned T cells and effectively inhibit the proliferation (see Figures 3B i-iii) .
- increasing the concentration of HDM in the assays was associated with a decrease in the inhibition mediated by the HA peptide in each case.
- Murine fibroblasts transfected with the HLA-D region genes, DRw52b, DR1 and DR2Dw2B5 were examined for their capacity to bind the HA analogue as de ⁇ scribed in Busch, R. , et al. , Int. Immunol., 2 ⁇ 442 (1990) .
- the fibroblasts were then washed and stained with fluorescein avidin D (Vector Labora ⁇ tories, CA) was added to the cells prior to a further incubation with fluorescein avidin D.
- HLA class II molecules To control for differential expression of HLA class II molecules on the fibroblasts, cells were incubated with a fluore- ⁇ ceinated monomorphic anti-HLA-DR antibody (L243, Becton Dickinson, CA) as described in Lampson, L.A. and Levy, R. , J. Immunol., 125: 293 (1980) . Stained cells were analyzed by flow cytometry using a FASCcan analyzer (Becton Dickinson) . Only viable cells, identified by their ability to exclude propidium iodide, were analyzed.
- the appropriate genes were transfected in murine fibroblasts.
- Murine fibroblasts transfected with the DRw52b gene were able to bind the HA peptide in a dose-dependent manner in contrast to the control fibroblasts expressing DR1 or the untransfected cell line (DAP3) , as determined by the level of fluor ⁇ escence as illustrated in Figure 4.
- the HA peptide was able to bind in a dose-dependent manner to murine fibroblasts transfected with DR2Dw2B5 genes, which were functionally able to present HDM to clone DE9.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Insects & Arthropods (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
Abstract
A method of reducing immune response to an allergen in which a non-allergen derived, non-stimulatory peptide which binds to specific MHC class II molecules of antigen presenting cells is used, as well as non-allergen derived, non-stimulatory peptides useful in the method.
Description
PEPTIDE-MEDIATED HYPOSENSITIZATION OF THE HUMAN T CELL RESPONSE TO DERMATOPHAGOIDES SPP. (HOUSE DUST MITE)
Background of the Invention The term "atopic allergy" is applied to a group of allergies, including asthma, hay fever, allergic rhinitis, urticaria (hives), eczema, conjunctivitis and food allergies, all of which are induced by environmental antigens. The mechanisms include the synthesis of specific immunoglobulin E (IgE) with the differentiation and growth of effector cells such as mast cells and eosiniphils. The activity of these effector cells is dependent upon T-helper (CD4+) cells and their products. In turn, the activation of CD4+ T-cells is dependent upon antigen receptors on T-cells recognizing peptide fragments of foreign proteins (allergens) in association with self gene products of the major histocompatibility complex (MHC) expressed on the surface of antigen presenting cells. Allergic IgE-mediated diseases are currently treated by desensitization procedures that involve the periodic injection of allergen components or extracts. Desensitization treatments may induce an IgG response that competes with IgE for allergen, or they may induce specific suppressor T-cells that block the synthesis of IgE directed against allergen. These procedures are not always effective and pose the risk of provoking an allergic response. A therapeutic treatment that would decrease or eliminate the allergic-immune response to a particular allergen, without altering the immune reactivity to other
foreign antigens or triggering an allergic response itself would be of great benefit to allergic individuals.
Summary of the Invention
The present invention is a method of reducing T cell response to a selected allergen, in which a non-allergen derived, non-stimulatory peptide is used and interferes with T cell recognition of the aller¬ gen, resulting in a decreased T cell response. The present invention is useful in reducing (decreasing or eliminating) hypersensitivity of an individual to an allergen. A non-allergen derived, non-stimulatory peptide is administered to the individual to modulate T cell recognition of the allergen and, as a result, to reduce the individual's immune response to the allergen. In the method of the present invention, the non-allergen derived, non-stimulatory peptide admin- istered is one which binds to selected MHC class II molecules of antigen presenting cells and, as a result, inhibits the specific T-helper cell response. The present invention further relates to peptides and compositions useful in the method of reducing hyper- sensitivity.
In particular, the present invention relates to a method of reducing hypersensitivity of an individual to Dermatophagoides spp. (house dust mite or HDM) . It also relates to non-HDM derived non-stimulatory peptides, such as non-stimulating peptide analogs of influenza haemagglutinin which bind to DRw52b class II molecules, useful in the present method.
In another embodiment, the invention relates to an in vitro method of determining the capability of a non-allergen derived, non-stimulatory peptide to reduce the immune response to an allergen. This is achieved by determining whether the peptide binds to specific MHC class II molecules of antigen presenting
cells and whether binding of the peptide to specific MHC class II molecules modulates the T-cell MHC-restricted recognition of the allergen, thereby reducing the immune response to the allergen. Currently used methods of achieving hyposensi- tization to allergens, including Dermatophagoides spp., depend upon the administration of the components or extracts of allergens. However, these components or extracts are not always successful and can themselves provoke allergic responses. The present invention provides an alternative approach to such therapy and is particularly advantageous because desensitization can be achieved while the risk of triggering an allergic response is reduced.
Brief Description of the Drawings
Figure 1 is a graphic representation of HA S-309 induced inhibition of the polyclonal T-cell response of dust mite allergic individuals to specific allergen.
Figure 2 is a graphic representation of HA S-309 modulation of polyclonal T-cell responses to Dermatophagoides spp., M. tuberculosis and PHA.
Figure 3 is a graphic representation of HA S-309 modulation of monoclonal T-cell responses to insolu- bilized anti-CD3 antibody and Dermatophagoides spp.
Figure 4 is a graphic representation of the binding of HA S-309 to DRw52b HLA class II molecules expressed on the surface of murine fibroblasts.
Detailed Description of the Invention
The present invention is based on the discovery that a non-allergen derived, non-stimulatory peptide is able to bind to selected MHC class II molecules and inhibit both polyclonal and monoclonal T cell response to an allergen (referred to as an allergen of interest) which causes a T cell response in allergic individuals. As described herein, it has been shown that a non-stimulatory peptide analogue derived from influenza virus hemagglutinin (HA) binds selected MHC class II molecules and inhibits the reponse of mite- specific CD4+ T cells restricted by the MHC class II molecules. As is also described herein, although polyclonal T cell responses were negatively modulated (decreased) by the peptide, recognition of common recall antigens remained intact. T-cell MHC- restricted recognition is defined as a response of a T-cell resulting from an interaction with a MHC class II molecule of an antigen presenting cell and an allergen derived peptide.
The present invention relates to a method of reducing (decreasing or eliminating) a specific allergic response by an individual to an allergen by administering to the individual a peptide which is not derived from the allergen to which the response occurs, is itself non-stimulatory, and binds to MHC class II molecules which also bind the allergen. In particular, the invention relates to a method of reducing T cell recognition of HDM through the use of a peptide analogue derived from influenza virus HA. As a result, an individual's sensitivity to an allergen such as HDM can be reduced by administering to the individual a therapeutically effective dose of
a non-allergen derived, non-stimulatory peptide, which binds to specific MHC class II molecules of antigen- presenting cells. This binding inhibits the T-cell response to the allergen and thereby, decreases or eliminates the allergic response.
The non-allergen derived, non-stimulatory peptide used in the present method is one derived from or having essentially the same sequence as a peptide from a source other than the allergen of interest. It can have the same (unmodified) amino acid sequence as occurs in the peptide from which it is derived or can have an altered amino acid sequence (i.e., is a peptide "analogue" which differs from the amino acid sequence as it occurs naturally by deletion, addition or substitution of at least one amino acid) . As used herein, the term "derived from" includes both amino acid sequences (peptides) physically obtained from an existing sequence (e.g., by cutting or cleaving using chemical or enzymatic processes) and amino acid sequences which are produced, using known methods such as genetic engineering techniques or synthetic chem¬ istry to have substantially the same sequence as that of an existing sequence. As used herein, the term peptide is intended to include both unmodified and modified amino acid sequences.
The non-allergen derived, non-stimulatory peptide can be any peptide that does not provoke a response to the allergen to which desensitization is desired, binds a site on a MHC class II surface molecule of an antigen-presenting cell to which the allergen can also bind, and inhibits the T-cell response to the aller¬ gen. In one embodiment of the invention a peptide
analogue (designated S-309) derived from the natural sequence of the carboxyl terminus of the HA-1 peptide of influenza hae agglutinin (residues 307-319, with the tryosine at position 309 substituted by serine) is used. An advantage of S-309 is that its binding is restricted to a particular MHC class II molecule, whereas the native peptide is non-restricted in the number of MHC class II molecules it has the capabity to bind. As described herein, this peptide analogue has been shown to bind class II molecules which also bind HDM and to inhibit the antigen- dependent re¬ sponse of cloned HDM specific T cells with the same restriction specificity. As described in the Exam¬ ples, the S-309 peptide analogue, having the sequence:
Pro-Lys-Ser-Val-Lys-Gln-Asn-Thr-Leu-Lys-Leu-Ala-Thr, 307 319
has been shown to inhibit polyclonal T cell responses to stimulation induced by D. pteronyssinus and mono¬ clonal T cell responses to stimulation induced by D. pteronyssinus and D. farinae. This suggests that the binding of the peptide to MHC surface molecules prevents activation of the majority of HDM reactive T cells. Possible mechanisms by which the activation of helper T-cells is inhibited include 1) competitive binding of the HA-1 peptide and the T-cell receptor for the MHC surface molecule, and 2) interference with the presentation of processed antigens of the allergen complexed to the MHC surface molecules.
A peptide analogue useful in the present method differs from the normally-occurring peptide by at
least one amino acid (e.g., an addition, deletion or substitution) . Alterations in the amino acid sequence can be made to enhance the ability of the peptide analogue to inhibit T cell response to the allergen. Peptides and peptide analogues can be prepared by a variety of known methods. For example, they can be prepared using Merrifield's procedure of solid-phase peptide synthesis (Merrifield, R.B., J. Am. Chem. Soc. , 86; 304 (1964), hereby incorporated by refer- ence) . The first step in the solid-phase synthesis of amino acid peptide analogues, as well as other pep¬ tides, is the formation of a covalent bond between the C-terminal protected amino acid of the chosen peptide sequence and the solid support or resin. The peptide chain is then build up residue by residue by repeti¬ tive cycles of deprotection, during which the N- ternamal Boc-protecting (N-tect-bitoxycarboxyl) group is removed by trifluoroacetic acid (TFA) . This is followed by neutralization with disopropylethylamine (DEA) of the amino group left as a salt and coupling of the next amino acid in the sequence. The cycle is repeated until the sequence is completed. After assembly is completed, the peptide is cleaved from the resin and purified. Alternatively, peptides useful in the present invention can be produced using genetic engineering techniques. For example, DNA encoding the desired amino acid sequence can be incorporated into an appropriate expression vector and introduced into a host cell suitable for expression of the encoded product.
Administration of the non-stimulatory peptide to an individual can be by any route by which a therapeu- tically effective quantity of the peptide can be delivered. For example, administration can be via a parenteral route, such as by subcutaneous, intravenous or intramuscular administration, transdermal passage or uptake from the respiratory tract. Administration can also be via the gastrointestinal tract, such as by oral or rectal administration. The form in which the peptide is administered (e.g., capsule, tablet, solution, emulsion) will depend, at least in part, on the route by which it is administered. For example, administration by injection would involve the use of physiologic saline or other physiological compatible carrier.
A therapeutically effective amount of a non- stimulatory peptide is that amount which will decrease or eliminate the T-helper cell response to a specific allergen. The therapeutically effective amount will be determined on an individual basis and will be based, at least in part, on consideration of the individual's size, the severity of symptoms to be treated, the result sought, the particular non- stimulatory peptide used, etc. The effective amount can be determined by one of ordinary skill in the art employing such factors and using no more than routine experimentation.
The non-allergen derived, non-stimulatory peptides used in the method of the present invention bind to ΪIHC class II molecules and interfere with the recognition of allergen MHC-molecule complexes by T-helper cells. As a consequence, the T-cell response
is inhibited. This inhibition is reflected by a lack of clonal expansion and the secretion of one or more lymphokines which are soluble factors that have multiple effects on B-cells and other T-cells. Lack of or decrease in a T-cell response to an allergen is referred to as a hyposensitization of the T-cells to the allergen.
Although the present invention is described in terms of non-allergen, non-stimulating peptides of influenza haemagglutinin which is used to modulate the immune response to HDM, it is also possible to identify other non-allergen, non-stimulatory peptides useful for the same purpose or for modulating immune responses to other allergens. Identification of other inhibitors of specific allergens can be achieved by 1) identifying the specificity of the restriction (MHC class II) molecules of importance with the specific allergen; 2) searching the database for peptides known to bind to these molecules; 3) synthesizing and testing the above peptides for their ability to inhibit binding of and/or recognition of the allergen in a competition assay; and 4) modifying peptides to produce peptide analogues with enhanced binding and/or biological activity. Alternatively, peptides can be randomly selected and screened for their capacity to bind specific MHC class II molecules and inhibit allergen-dependent T-cell proliferation.
The invention is further illustrated by the following specific examples, which are not intended to be limiting in any way.
EXAMPLE 1 Peptide Inhibition of Polyclonal T Cell
Responses Antigens
Lyophilized extracts of Dermatophagoides farinae (D. farinae) and Dermatophagoides pteronyssinun (D. pteronyssinun) were the general gifts of Drs. Lowenstein and Schou (ALK, Horsholm, Denmark) and Bencard (Brentford, Middlesex, U.K.), respectively. A soluble extract of Mycobacteriu tuberculosis (MTSE) was generously provided by Dr. A. Rees (M.R.C.
Tuberculosis Unit, Hammersmith Hospital, U.K.). The HA peptide analogue (residues 307-319: serine at 309) and the keratin peptide (residues 1-9) were synthesized using solid phase techniques (Barany, G. and Merrifield, R. , Solid phase peptide synthesis In: Gross, E. Meinhofer, J. (Eds), The Peptides, New York, Academic Press (1979) hereby incorporated by reference) on an Applied Biosystems Peptide Synthesizer with Pam resins, t-Boc protected amino acids, and commercially available reagents (Applied Biosystems, Foster City, CA) . Peptides were kindly provided by J. Rothbard (ImmuLogic Pharmaceutical Corporation, Palo Alto, CA) . The T cell mitogen phytahaemagglutinin (PHA-P) was purchased from Sigma Chemicals Co. (St. Louis, MO) , and the murine monoclonal anti-CD3 antibody (OKT3) purified from the hybridoma cell line purchased from the ATCC (Rockville, MD) .
Preparation of Lymphocytes and Donor Characterization
Peripheral blood mononuclear leucocytes (PBMC) obtained from unmedicated atopic adults with symptomatic HDM allergy (perennial rhinitis) were isolated by centrifugation on a discontinuous gradient of Ficoll-Paque (Pharmacia) . All subjects had positive skin prick tests to Dermaphatogoides spp., and positive HDM radioallergosorbent tests. PBMC were resuspended in complete medium, RPMI-1640 supplemented with A+ or AB+ serum, 2mM L-glutamine and 100 IU/ml of penicillin/streptomycin.
Isolation of Antigen Reactive T cell Clones
HDM specific T cell clones were isolated as described previously (O'Hehir, R.E., et al. ,
Immunobiology, 62: 635 (1987)). Briefly, PBMC (2.5 X 5 10 /ml) were stimulated with an optimal concentration of D farinae for 7 days in complete medium.
Lymphoblasts enriched on Ficoll-Paque were maintained as a long term line in the presence of irradiated
(2500 Rads) autologous PBMC, D farinae and interleukin 2 (IL-2, 10% v/v; Lymphocult-T, Biotest Folex,
Frankfurt, FRG) and then cloned by limiting dilution from the T cell line. For cloning, viable cells (0.3 cells/well) were plated in Microtest II trays together with irradiated autologout PBMC (5 X 10 /ml) , D. farinae and IL-2. After 7 days, growing clones were transferred to flat bottom 96-well microtitre trays and, subsequently, to 24 well trays. At each transfer, the clones received filler cells, antigen and IL-2. The clones were maintained and expanded by the addition of IL-2 every 3-4 days, and antigen together with filler cells every 7 days. Prior to
their use in proliferation assays, the T cell clones were rested for 6-8 days after the last addition of filler cells and antigen. A number of T cell clones specific for D. Farinae and others cross-reactive with D. farinae and D. pteronyssiunus were isolated, and the MHC class II restriction specificities of these clones were mapped (O'Hehir, R.E., et al. , Immunology, 64: 627 (1988)).
Proliferation Assays
5 Polyclonal Responses: PBMC (2.5 X 10 /ml) were cultured with soluble antigen in a total volume of 200 μl of complete medium in 96-well round bottom plates.
Peptides were added at various concentrations to selected wells at the initiation of cultures. After 6 days, tritiated methyl thymidine (lμCi [ H] .
TdR/well; Amersham International, Amersham, U.K.) was added to the cultures for 8-16 hours and then the cells were harvested onto glass fibre filters. Proliferation as correlated with [ H] -TdR incorporation was measured at day 7 by liquid scintillation spectroscopy. The results are expressed as mean counts per minute (cpm) for triplicate cultures.
Peptide Inhibition of Polyclonal T Cell Responses Stimulation induced with D. pteronyssinus:
Marked proliferation was induced in all cases when PBMC isolated from 5 atopic individuals with symptomatic perennial rhinitis were stimulated with D. pteronyssinus at an optimal concentration (range 3-12 μug/ l) . The addition of the HA peptide analogue.
with the tyrosine at position 309 substituted by serine, to the cultures resulted in marked inhibition of the proliferative response over a concentration range (0.5-100 μg/ml) . In the presence of the HA peptide, the percentage proliferation as compared to the maximal HDM response achieved varied from 10 to 34%. As illustrated in Figure 1 (striped bar) , PBMC stimulated with HDM in the presence of peptide analogue; open bar: PBMC stimulated with HDM in the absence of peptide analogue) . In contrast, coculture of the keratin peptide and D. pteronyssinus over the same concentration range failed to decrease the observed response as illustrated in Figure 2A. In all cases, PBMC failed to proliferate to either of the peptides alone.
Stimulation induced with M. tuberculosis soluble extract: Polyclonal T cell proliferation observed in response to stimulation with MTSE (3 μg/ml) was only minimally inhibited by the HA analogue. The maximal inhibitory effect obtained was only 25% (BS) and 40% (MR) at 100 μg/ml, with 13% (BS) and 28% (MR) inhibition at 10 μg/ml. No inhibition of the anti-mycobacterial T cell response was observed in the presence of the control keratin peptide as illustrated in Figure 2B.
PHA and anti-CD3 induced activation: PHA at a concentration of 1 μg/ml induced marked proliferation in each subject (see Figures 2C i and ii) . No inhibitory effect was observed with the addition of either peptide. Similarly, both peptides failed to inhibit the proliferative response of T cells stimulated directly with immobilized anti-CD3 antibody
and IL-2 that mimics the recognition of peptide/MHC class II complexes as illustrated in Figure 3A i.
EXAMPLE II Peptide Inhibition of Monoclonal T Cell
Responses Proliferation Assays Monoclonal Responses: Antigens and antigen reactive T cell clones were obtained as described in
4 Example I. Cloned T cells (5 X 10 /ml) were cultured with soluble antigen in the presence of irradiated
5 autologous PBMC (1.25 X 10 /ml) in a total volume of 200 μl of complete medium in 96-well round bottom plates. Peptides were added to selected wells as described for polyclonal responses. After 60 hours incubation, [ H] -TdR was added to the cultures for
8-16 hours and then they were harvested as described for the polyclonal T cell proliferation assays.
Cloned T cells (DE9; cross-reactive for both species of Dermatophagoides spp., restricted by products of the Bl gene locus DRwl2 and degenerate in its restriction specificity for DR2 subtypes and DR8 (O'Hehir, R.E. , supra (1988), proliferated markedly to
D. pteronyssinus (3 μg/ml) presented by autologous irradiated PBMC as accessory cells. The addition of the HA analogue resulted in marked inhibition of the proliferative response in a dose dependent manner, with 60% inhibition at 100 μg/ml. In contrast, coculture using the keratin peptide failed to inhibit the HDM induced proliferation as illustrated in Figure
3A i.
D. farinae specific T cell clones (DE12 and DE47) restricted by the DRAB3 gene product DRw52b and T cell
clone DE9 were stimulated with increasing concentra¬ tions of stimulating antigen (D. farinae) in the presence of autologous irradiated PBMC as a source of antigen presenting cells. To these cultures the HA analogue was added at a fixed concentration (100 μg/ml) and T cell proliferation determined. The HA peptide was able to compete with HDM for presentation to the cloned T cells and effectively inhibit the proliferation (see Figures 3B i-iii) . However, increasing the concentration of HDM in the assays was associated with a decrease in the inhibition mediated by the HA peptide in each case.
EXAMPLE III Binding of HA Peptide to Antigen
Presenting Cells Expressing DRw52b MHC Class II Molecules
The cloning of the DRIDwl, DR2Dw2B5 and DRw52b genes and their co-transfection with the DRA gene into the Ltk fibroblast cell line (DAP3) have been de¬ scribed in Rothbard, J.B., et al., Cell, 52: 515 (1988); Rabourdin-Combe, C. and Mach, B., Nature, 303: 670 (1983); Borsh, J. , et al. , J. Exp. Med., 162: 105 (1985); Wilkinson, D., et al. , J. Exp. Med., 167: 1442 (1988) . The transfected fibroblasts were the generous gifts of Drs. R. Leckler, J. Trowsdale and B. Mach. Murine fibroblasts transfected with the HLA-D region genes, DRw52b, DR1 and DR2Dw2B5 were examined for their capacity to bind the HA analogue as de¬ scribed in Busch, R. , et al. , Int. Immunol., 2} 442 (1990) . After incubation with peptide, containing long chain biotin at the amino terminus, over a
concentration range, the fibroblasts were then washed and stained with fluorescein avidin D (Vector Labora¬ tories, CA) was added to the cells prior to a further incubation with fluorescein avidin D. To control for differential expression of HLA class II molecules on the fibroblasts, cells were incubated with a fluore- εceinated monomorphic anti-HLA-DR antibody (L243, Becton Dickinson, CA) as described in Lampson, L.A. and Levy, R. , J. Immunol., 125: 293 (1980) . Stained cells were analyzed by flow cytometry using a FASCcan analyzer (Becton Dickinson) . Only viable cells, identified by their ability to exclude propidium iodide, were analyzed.
To examine the binding of the HA peptide to DRw252b in isolation from other HLA class II mole¬ cules, the appropriate genes were transfected in murine fibroblasts. Murine fibroblasts transfected with the DRw52b gene were able to bind the HA peptide in a dose-dependent manner in contrast to the control fibroblasts expressing DR1 or the untransfected cell line (DAP3) , as determined by the level of fluor¬ escence as illustrated in Figure 4. Similarly, the HA peptide was able to bind in a dose-dependent manner to murine fibroblasts transfected with DR2Dw2B5 genes, which were functionally able to present HDM to clone DE9.
Claims
1. A method of reducing T cell response to a selected allergen, comprising contacting T cells with a non-allergen derived, non-stimulatory peptide in the presence of the selected allergen and antigen-presenting cells, under conditions appropriate for interference by the non-allergen derived, non-stimulatory peptide with T cell response to the selected allergen.
2. The method of Claim 1 wherein the selected allergen is a house dust mite allergen and the non-allergen derived, non-stimulatory peptide is an influenza virus HA peptide.
3. The method of Claim 2 wherein the influenza virus HA peptide has the following sequence:
Pro-Lys-Ser-Val-Lys-Gln-Asn-Thr-Leu-Lys-Leu-Ala— Thr.
4. A method of inhibiting polyclonal T cell response to stimulation by a selected allergen, comprising combining T cells stimulated by the selected allergen with a non-allergen derived, non-stimulatory peptide which interferes with T cell recognition of the selected allergen.
5. The method of Claim 4 wherein the selected allergen is a house dust mite allergen and the non-allergen derived, non-stimulatory peptide is an influenza virus HA peptide.
6. The method of Claim 5 wherein the influenza virus HA peptide has the following sequence: Pro-Lys-Ser-Val-Lys-Gln-Asn-Thr-Leu-Lys-Leu-Ala— Thr.
7. A non-allergen derived, non-stimulatory peptide which inhibits T cell response to a selected allergen.
8. The non-allergen derived, non-stimulatory peptide of Claim 7 which is an influenza virus HA peptide.
9. The non-allergen derived, non-stimulatory peptide of Claim 8 which has the following sequence: Pro-Lys-Ser-Val-Lys-Gln-Asn-Thr-Leu-Lys-Leu-Ala— Thr.
10. A method of reducing, in an individual, immune response to an allergen, comprising administering to the individual a therapeutically effective amount of a non-allergen derived, non-stimulatory peptide which binds to specific MHC class II molecules of antigen-presenting cells, wherein binding of the non-allergen derived, non-stimulatory peptide to specific MHC class II molecules modulates T cell MHC-restricted recognition of the allergen, thereby reducing the immune response of the individual to the allergen.
11. A method of reducing, in an individual, immune response to an allergen of house dust mite, comprising administering to the individual a therapeutically effective amount of a non- allergen derived, non-stimulatory peptide which binds to specific MHC class II molecules of antigen-presenting cells, wherein binding of the non-allergen derived, non-stimulatory peptide to specific MHC class II molecules modulates T cell MHC-restricted recognition of the allergen of house dust mite, thereby reducing the immune response of the individual to the house dust mite allergen.
12. The method of Claim 11 wherein the non-allergen, non-stimulatory peptide is an influenza virus HA peptide.
13. The method of Claim 12 wherein the influenza virus HA peptide has the amino acid sequence: Pro-Lys-Ser-Val-Lys-Gln-Asn-Thr-Leu-Lys-Leu-Ala— Thr.
14. The method of Claim 11 wherein said MHC class II molecules are products of HLA-DRAB3 class II genes, DRw52 class II molecules.
15. A method of Claim 11 wherein the MHC class II molecules are products of the DRAB1 genes, DRwl2 class II molecules.
16. A method of reducing, in an individual, immune response to an allergen, comprising administering to the individual a therapeutically effective amount of a non-allergen derived, non-stimulatory peptide of haemagglutinin which binds to DRw52 class II molecules of antigen-presenting cells, wherein binding of the non-allergen derived, non-stimulatory peptide to DRw52 MHC class II molecules modulates T cell DRw52-restricted response to house dust mites, thereby reducing the immune response of the individual to house dust mites.
17. A method of determining the capability of a non-allergen derived, non-stimulatory peptide to reduce immmune response to an allergen, comprising determining whether the peptide binds to specific MHC class II molecules of antigen presenting cells and whether binding of the peptide to the specific MHC class II molecules modulates T cell MHC-restricted recognition of the allergen, thereby reducing the immune response to the allergen.
18. A method of determining the capability of a non-house dust mite derived, non-stimulatory peptide to reduce the immune response to a house dust mite allergen, comprising determining whether the peptide binds to specific MHC class II molecules of antigen presenting cells and whether binding of the peptide to the specific MHC class II molecules modulates T cell MHC-restricted recognition of house dust mite, thereby reducing immune response to house dust mite.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63869791A | 1991-01-08 | 1991-01-08 | |
US638,697 | 1991-01-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992011859A1 true WO1992011859A1 (en) | 1992-07-23 |
Family
ID=24561065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/000205 WO1992011859A1 (en) | 1991-01-08 | 1992-01-08 | Peptide-mediated hyposensitization of the human t cell response to dermatophagoides spp. (house dust mite) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1992011859A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026980A2 (en) * | 1994-04-01 | 1995-10-12 | Immulogic Pharmaceutical Corporation | Haptenated peptides and uses thereof |
US5460977A (en) * | 1992-08-14 | 1995-10-24 | Torii & Co. | Peptide having allergenicity |
WO1999034826A1 (en) * | 1998-01-09 | 1999-07-15 | Circassia Limited | Methods and compositions for desensitisation |
US6737406B1 (en) | 1996-03-21 | 2004-05-18 | Circassia, Ltd. | Cryptic peptides and method for their identification |
US7485708B2 (en) | 1996-09-23 | 2009-02-03 | University Of Arkansas | Nucleic acids encoding ara h 3 polypeptides |
US7879977B2 (en) | 1998-01-31 | 2011-02-01 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
US8246945B2 (en) | 2000-04-06 | 2012-08-21 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
-
1992
- 1992-01-08 WO PCT/US1992/000205 patent/WO1992011859A1/en active Application Filing
Non-Patent Citations (5)
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5460977A (en) * | 1992-08-14 | 1995-10-24 | Torii & Co. | Peptide having allergenicity |
WO1995026980A2 (en) * | 1994-04-01 | 1995-10-12 | Immulogic Pharmaceutical Corporation | Haptenated peptides and uses thereof |
WO1995026980A3 (en) * | 1994-04-01 | 1995-12-07 | Immulogic Pharma Corp | Haptenated peptides and uses thereof |
US6737406B1 (en) | 1996-03-21 | 2004-05-18 | Circassia, Ltd. | Cryptic peptides and method for their identification |
US7485708B2 (en) | 1996-09-23 | 2009-02-03 | University Of Arkansas | Nucleic acids encoding ara h 3 polypeptides |
WO1999034826A1 (en) * | 1998-01-09 | 1999-07-15 | Circassia Limited | Methods and compositions for desensitisation |
GB2348808A (en) * | 1998-01-09 | 2000-10-18 | Circassia Ltd | Methods and compositions for desensitisation |
GB2348808B (en) * | 1998-01-09 | 2003-03-19 | Circassia Ltd | Methods and compositions for desensitisation |
US7879977B2 (en) | 1998-01-31 | 2011-02-01 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
US8246945B2 (en) | 2000-04-06 | 2012-08-21 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Widmann et al. | T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides | |
JP2023515386A (en) | Regulatory T cell epitopes and detolerizing SARS-COV-2 antigens | |
Udaka et al. | Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. | |
Berzofsky et al. | Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans | |
Solinger et al. | T-lymphocyte response to cytochrome c. I. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histocompatibility complex-linked immune response genes. | |
JP3782100B2 (en) | HLA-binding peptide and use thereof | |
Manca et al. | The naive repertoire of human T helper cells specific for gp120, the envelope glycoprotein of HIV. | |
JP2008195718A (en) | T-cell epitope peptide | |
Cao et al. | Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes. | |
O'HEHIR et al. | House dust mite allergy: from T‐cell epitopes to immuno‐therapy | |
WO1995026980A2 (en) | Haptenated peptides and uses thereof | |
JPH03503166A (en) | Synthetic antigens that evoke anti-HIV responses | |
US5935579A (en) | AIDS therapy and vaccine | |
Ku et al. | Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen | |
Rogers et al. | Recombinant Fel d I: Expression, purification, IgE binding and reaction with cat-allergic human T cells | |
JPH05500653A (en) | How to treat rheumatoid arthritis | |
WO1992011859A1 (en) | Peptide-mediated hyposensitization of the human t cell response to dermatophagoides spp. (house dust mite) | |
O'Hehir et al. | An in vitro model of peptide-mediated immunomodulation of the human T cell response to Dermatophagoides spp (house dust mite) | |
Protti et al. | Myasthenia gravis. T epitopes on the delta subunit of human muscle acetylcholine receptor. | |
Hickman et al. | Use of synthetic peptides to identify measles nucleoprotein T-cell epitopes in vaccinated and naturally infected humans | |
Chin et al. | Mimicking the humoral immune response in vitro results in antigen‐specific isotype switching supported by specific autologous T helper cells: generation of human HIV‐1‐neutralizing IgG monoclonal antibodies from naive donors | |
JP4218987B2 (en) | Peptide immunotherapy treatment | |
WO1990008161A1 (en) | Peptide-mediated modulation of t-cell recognition as a means of affecting immune responses | |
Sheil et al. | Identification of an autologous insulin B chain peptide as a target antigen for H-2Kb-restricted cytotoxic T lymphocytes. | |
JP3474898B2 (en) | T cell epitope peptide of cedar pollen allergen and its analog peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase |